These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11514474)

  • 21. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: initiate treatment early or wait for the catheterization laboratory?
    Harnick DJ; Vorchheimer DA
    Curr Cardiol Rep; 2001 Sep; 3(5):355-61. PubMed ID: 11504571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes.
    Boersma E
    J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743
    [No Abstract]   [Full Text] [Related]  

  • 25. 'I can see clearly now': a new view on the use of IV GP IIb/IIIa inhibitors in acute coronary syndromes.
    Antman EM
    Eur Heart J; 2002 Sep; 23(18):1408-11. PubMed ID: 12208217
    [No Abstract]   [Full Text] [Related]  

  • 26. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Berkowitz SD
    Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cold start for oral glycoprotein IIb/IIIa antagonists.
    Curtin R; Fitzgerald DJ
    Eur Heart J; 2000 Dec; 21(24):1992-4. PubMed ID: 11102247
    [No Abstract]   [Full Text] [Related]  

  • 28. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
    Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
    N Engl J Med; 1998 Aug; 339(7):436-43. PubMed ID: 9705684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors.
    Jafary FH; Kimmelstiel CD
    J Thromb Thrombolysis; 2000 Feb; 9(2):163-74. PubMed ID: 10613998
    [No Abstract]   [Full Text] [Related]  

  • 30. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
    Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
    Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
    N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of glycoprotein IIb/IIIa inhibitors in unstable angina: current perspectives.
    Scapa E; Battler A; Hasdai D
    Cardiol Rev; 2000; 8(6):348-53. PubMed ID: 11208255
    [No Abstract]   [Full Text] [Related]  

  • 33. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet GP IIb/IIIa inhibition in unstable angina and non-ST segment elevation MI: application of the ACC/AHA guidelines.
    Young JJ; Choo JK; Kereiakes DJ; ;
    J Invasive Cardiol; 2003 Feb; 15(2):102-7; quiz 108. PubMed ID: 12556626
    [No Abstract]   [Full Text] [Related]  

  • 35. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
    Harrington RA
    Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of glycoprotein IIb/IIIa receptor inhibitors in unstable angina.
    Ageno W; Turpie AG
    G Ital Cardiol; 1999 Nov; 29(11):1357-65. PubMed ID: 10609142
    [No Abstract]   [Full Text] [Related]  

  • 37. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
    Bosanquet N; Jönsson B; Fox KA
    Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological treatment of acute coronary syndromes.
    Hughes K
    Prof Nurse; 2003 Jan; 18(5):296-9. PubMed ID: 12599964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The year in non-ST-segment elevation acute coronary syndromes.
    Giugliano RP; Braunwald E
    J Am Coll Cardiol; 2005 Sep; 46(5):906-19. PubMed ID: 16139143
    [No Abstract]   [Full Text] [Related]  

  • 40. Timing of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Naina HV; Harris S; Singla A
    JAMA; 2007 Jul; 298(1):37; author reply 37-8. PubMed ID: 17609485
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.